A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

被引：2
|
作者：
Sochacki, Andrew L. [1 ]
Burger, Jan A. [2 ]
Ludwig, Carrianne [3 ]
Assaily, Wissam [3 ]
Munasinghe, Wijith [3 ]
Pappano, William [3 ]
Greenberg, Edward [3 ]
Will, Christine [3 ]
Thompson, Meghan C. [4 ]
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Makita, Shinichi
    Yamamoto, Go
    Maruyama, Dai
    Asano-Mori, Yuki
    Kaji, Daisuke
    Ananthakrishnan, Revathi
    Ogasawara, Ken
    Stepan, Lara
    Schusterbauer, Claudia
    Rettby, Nils
    Hasskarl, Jens
    Izutsu, Koji
    CANCER MEDICINE, 2022, 11 (24): : 4889 - 4899
  • [32] Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma
    Munakata, Wataru
    Shirasugi, Yukari
    Tobinai, Kensei
    Onizuka, Makoto
    Makita, Shinichi
    Suzuki, Rikio
    Maruyama, Dai
    Kawai, Hidetsugu
    Izutsu, Koji
    Nakanishi, Tadashi
    Shiba, Sari
    Hojo, Seichiro
    Ando, Kiyoshi
    CANCER SCIENCE, 2021, 112 (03) : 1123 - 1131
  • [33] A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
    Younes, A.
    Vose, J. M.
    Zelenetz, A. D.
    Smith, M. R.
    Burris, H. A.
    Ansell, S. M.
    Klein, J.
    Halpern, W.
    Miceli, R.
    Kumm, E.
    Fox, N. L.
    Czuczman, M. S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (12) : 1783 - 1787
  • [34] A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
    A Younes
    J M Vose
    A D Zelenetz
    M R Smith
    H A Burris
    S M Ansell
    J Klein
    W Halpern
    R Miceli
    E Kumm
    N L Fox
    M S Czuczman
    British Journal of Cancer, 2010, 103 : 1783 - 1787
  • [35] Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
    Davids, Matthew S.
    Roberts, Andrew W.
    Kenkre, Vaishalee P.
    Wierda, William G.
    Kumar, Abhijeet
    Kipps, Thomas J.
    Boyer, Michelle
    Salem, Ahmed Hamed
    Pesko, John C.
    Arzt, Jennifer A.
    Mantas, Margaret
    Kim, Su Y.
    Seymour, John F.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4690 - 4695
  • [36] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Fayad, Luis
    McLaughlin, Peter
    Romaguara, Jorge E.
    Hagemeister, Fredrick
    Goy, Andre
    Neelapu, Sattva
    Samaniego, Felipe
    Walker, Pamela L.
    Wang, Michael
    Rodriguez, Maria A.
    Tong, Ann T.
    Pro, Barbara
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 502 - 505
  • [37] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Weekly Temsirolimus and Bortezomib For Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Phase II Study
    Fenske, Timothy S.
    Kim, Kyung Mann
    Zhang, Chong
    Farnen, John P.
    Onitilo, Adedayo A.
    Blank, Jules H.
    Ahuja, Harish
    Wassenaar, Tim
    Qamar, Rubina
    Mansky, Patrick
    Traynor, Anne
    Mattison, Ryan J.
    Kahl, Brad S.
    BLOOD, 2013, 122 (21)
  • [39] Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan
    Izutsu, Koji
    Ando, Kiyoshi
    Nishikori, Momoko
    Shibayama, Hirohiko
    Teshima, Takanori
    Kuroda, Junya
    Kato, Koji
    Imaizumi, Yoshitaka
    Nosaka, Kisato
    Sakai, Rika
    Hojo, Seiichiro
    Nakanishi, Tadashi
    Rai, Shinya
    CANCER SCIENCE, 2021, 112 (09) : 3627 - 3635
  • [40] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345